Atomo Diagnostics, a Sidney, Australia-based medical device company, raised A$4.5m in equity funding.
Backers included New York-based Global Health Investment Fund (GHIF), as well as a company associated with former Managing Director and CEO of Macquarie Group Limited, Mr. Allan Moss AO. In conjunction with the funding, Global Health Investment Fund Managing Partner Dr. Curt LaBelle will join Atomo’s board.
The company intends to use the funds to further expand its presence in the global health market.
Led by Chairman John Keith, Atomo Diagnostics is commercializing a range of innovative diagnostic devices, based on the AtomoRapid platform, which enables care testing from a small drop of blood from finger.
The investment followed receipt of a US$6m (A$7.8m) loan by GHIF in January 2016.